Fig. 7: Impacts of CTSH and PTGES3 on NSCLC cell proliferation, migration, and necroptosis. | npj Precision Oncology

Fig. 7: Impacts of CTSH and PTGES3 on NSCLC cell proliferation, migration, and necroptosis.

From: Integrating bulk, single-cell, and spatial transcriptomics to identify and functionally validate novel targets to enhance immunotherapy in NSCLC

Fig. 7: Impacts of CTSH and PTGES3 on NSCLC cell proliferation, migration, and necroptosis.The alternative text for this image may have been generated using AI.

a CTSH and PTGES3 in normal lung epithelial cells and indicated NSCLC cell lines were analyzed using Western blot. b, c The efficacy of CTSH overexpression in H1299 cells and PTGES3 knockdown in A549 cells was confirmed by qRT-PCR (b) and Western blot analysis (c). d, e CCK-8 assays evaluated the impact of CTSH overexpression (d) and PTGES3 knockdown (e) on NSCLC cell proliferation. f, g Transwell assays (f) and wound healing assays (g) were conducted to investigate the effects of CTSH overexpression and PTGES3 knockdown on cell migration against their respective controls. h–k LDH release assays measured cell membrane damage resulting from CTSH overexpression (h, i) or PTGES3 knockdown (j, k) and the counteractive effects of NSA (15 μM) and RIPA-56 (1.0 μM). l–o Western blot analysis detected levels of necroptosis biomarkers in cells with CTSH overexpression (l, m) and PTGES3 knockdown (n, o), following treatment with varying concentrations of necrosulfonamide (NSA) and RIPA-56, necroptosis inhibitors, for 24 h. p, q Co-immunoprecipitation (Co-IP) results demonstrated that CTSH overexpression (p) and PTGES3 knockdown (q) enhanced the interaction of RIPK3 and MLKL with RIPK1. *P < 0.05, **P < 0.01, ***P < 0.001.

Back to article page